Source comparison
MK-677 vs Growth Hormone Peptides: Bioavailability, Stability, and Protocol Design
Administration Route Oral (capsule or liquid) Subcutaneous injection Storage Requirement Room temperature stable Refrigeration required (2–8°C) Half-Life 24 hours (once-daily dosing) 2–4 hours (multiple daily doses) 3–4 hours (daily injection) Mechanism Ghreli
This comparison does not assign a generated winner or score.
- Administration Route
- Oral (capsule or liquid)
- Subcutaneous injection
- Storage Requirement
- Room temperature stable
- Refrigeration required (2–8°C)
- Half-Life
- 24 hours (once-daily dosing)
- 2–4 hours (multiple daily doses)
- 3–4 hours (daily injection)
- Mechanism
- Ghrelin receptor agonist (stimulates endogenous GH pulses)
- GHRH analogue (stimulates endogenous GH pulses)
- Direct GH replacement (bypasses pituitary)
- IGF-1 Elevation
- 40–90% increase from baseline
- 30–70% increase from baseline
- 100–300% increase (dose-dependent)
- Pulsatile GH Secretion
- Preserved (maintains circadian rhythm)
- Preserved (mimics natural pulses)
- Abolished (constant elevation)
- Appetite Effect
- Significant increase (ghrelin mimetic)
- Minimal to none
- Glucose Handling
- Transient insulin resistance (first 4–8 weeks)
- Minimal impact
- Significant insulin resistance (dose-dependent)
- Regulatory Axis Suppression
- None (no negative feedback on pituitary)
- None (stimulates, doesn't replace)
- Significant (suppresses endogenous GH)
- Compliance Burden
- Low (oral, once-daily)
- Moderate (injection, 1–2x daily)
- Moderate (injection, daily)
- Research Use Case
- Long-duration studies, metabolic research, compliance-limited populations
- Short-duration interventions, precise GH pulse control
- Direct GH replacement studies, severe deficiency models
- Bottom Line
- Best for studies where injection compliance or cold-chain storage is limiting; appetite and glucose effects must be controlled for
- Best when precise control over GH pulse timing is required; injection burden manageable
- Best for direct GH replacement models; highest IGF-1 elevation but also highest risk of axis suppression
- MK-677's primary advantage over peptide secretagogues is oral bioavailability. Peptides like Ipamorelin and CJC-1295 NO DAC require subcutaneous injection because gastric acid and proteolytic enzymes in the GI tract degrade peptide bonds within minutes. MK-677 is a non-peptide small molecule—it survives first-pass metabolism and achieves 60–70% oral bioavailability, comparable to most pharmaceutical drugs. This makes it uniquely suited for long-duration studies where daily injections would compromise compliance or introduce confounding stress responses.
- The 24-hour half-life of MK-677 allows once-daily dosing, whereas peptide secretagogues typically require dosing two to three times daily to maintain elevated GH levels. For protocols spanning months or years, this difference is operationally significant. However, MK-677's longer half-life also means slower washout—if an adverse event occurs or a protocol requires termination, it takes 4–5 days for MK-677 to clear the system, compared to 12–18 hours for peptides.
- One critical trade-off: MK-677 cannot be pulsed on-demand the way peptide secretagogues can. Peptides like ipamorelin allow researchers to time GH secretion precisely—administering doses before sleep to amplify nocturnal GH peaks, or pre-exercise to study acute lipolytic effects. MK-677's 24-hour half-life means it produces sustained elevation throughout the day, which may obscure circadian patterns or prevent isolation of specific GH pulse effects. For studies requiring temporal precision, peptide secretagogues retain an advantage despite the logistical burden.